Analysen | Apotheken | Arzt | Interaktionen | Medikamente | MiGeL | Services | Spital | Zulassungsi.
Fachinformation zu Omnitrope® 5/10/15 mg, Injektionslösung:Sandoz Pharmaceuticals AG
Vollst. FachinformationDDDÄnderungen anzeigenDrucken 
Fahrtücht.Unerw.WirkungenÜberdos.Eigensch.Pharm.kinetikPräklin.Sonstige H.Swissmedic-Nr.
PackungenReg.InhaberStand d. Info. 
H01AC01 - SomatropinATC-DDD Version 2016. Source: WHO
H - Systemic Hormonal Preparations, Excl. Sex Hormones and Insulins

This group comprises all hormonal preparations for systemic use, except:
- Insulins, see A10.
- Anabolic steroids, see A14.
- Catecholamines, see C01C and R03C.
- Sex hormones, see G03.
- Sex hormones used in treatment of neoplastic diseases, see L02.
- Metreleptin used for treatment of complications of leptin deficiency in patients with generalised lipodystrophy is classified in A16AA.

The DDDs are generally based on the treatment or diagnosis of endocrine disorders.

H01 - Pituitary and Hypothalamic Hormones and Analogues
H01A - Anterior Pituitary Lobe Hormones and Analogues

This group comprises anterior pituitary lobe hormones; extracts, purified natural hormones and synthetic analogues.
Somatropin antagonists are classified in H01AX.

H01AC - Somatropin and Somatropin Agonists

Mecasermin (insulin like growth factor) is classified in this group since it is used on the same indications as somatropin and somatrem. High strength preparations of sermorelin are classified here.
Low strength preparations used as diagnostic agents for pituitary function are classified in V04CD.
Tesamorelin used in the treatment of HIV patients with lipodystrophy is classified in this group.

The DDDs are based on the treatment of growth retardation in children with a body weight of 25 kg.

H01AC01 - Somatropin
2 UP 
2018 ©ywesee GmbH
Einstellungen | Hilfe | FAQ | Anmeldung | Kontakt | Home